Compound Taxus chinensis Capsule Combined with Chemotherapy for Non-Small-Cell Lung Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials
Table 1
Main features of the studies included in the current meta-analysis.
Reference
Design
Sample size (T/C)
Outcome measures
Intervention
Course of treatment
Cancer staging
Cao, 2016
RCT
29/29
DCR; ORR; KPS
T: CTCC + DP; C: DP
6 weeks
Advanced
Gong, 2018
RCT
36/36
DCR; ORR; QOL; adverse reaction rate
T: CTCC + GP; C: GP
12 weeks
Advanced
Li, 2017
RCT
42/42
DCR; ORR; tumor markers; Adverse reaction rate
T: CTCC + GP; C: GP
12 weeks
III, IV
Ren, 2018
RCT
38/38
DCR; ORR; KPS; tumor markers
T: CTCC + DP; CTCC + GP; CTCC + AP; C: DP; GP; AP
6 weeks
III, IV
Zhang H., 2017
RCT
30/30
DCR; ORR; adverse reaction rate; Immune function
T: CTCC + GP + Endostar; C: GP + Endostar
12 weeks
III, IV
Zhang X., 2015
RCT
30/30
DCR; ORR; KPS; maximum diameter of tumor; tumor markers
T: CTCC + TP/Paclitaxel plus nedaplatin; C: TP/Paclitaxel plus nedaplatin
8 weeks
II, III, IV
RCT: randomized controlled trial; T/C: treatment group/control group; CTCC: compound Taxus chinensis capsule; DCR: disease control rate; ORR: objective response rate; QOL: quality of life; KPS: Karnofsky health score; adverse reaction rate; tumor markers; immune function; Serum SIL-2R and IGF-1 levels; the area of cancer focal area; maximum diameter of tumor; GP: gemcitabine plus cisplatin; DP: docetaxel plus cisplatin; TC: paclitaxel plus carboplatin; TP: paclitaxel plus cisplatin; AP: pemetrexed plus cisplatin.
